The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | Evaluating AI-driven virtual tumor boards in MDS
In this video, David Swoboda, MD, Tampa General Hospital Cancer Center, Tampa, FL, discusses the development of a novel virtual tumor board designed to improve diagnosis, prognosis, and treatment recommendations in myelodysplastic syndromes (MDS). This multi-agent platform incorporates moderator, diagnostic, prognostic, treatment, and clinical trial agents. This platform was tested on 30 generated patient cases and demonstrated significantly improved outputs compared with generalized large language models, such as ChatGPT. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
